George A. Hyman, M.D.; Algernon B. Reese, M.D.
JAMA. 1956;162(15):1368-1373. doi:10.1001/jama.1956.02970320016005.
Text Size: A A A
Published online

† Retinoblastoma in 50 children between the ages of 2 months and 7 years was treated by a combination of radiotherapy and triethylene melamine. This series included only cases in which the disease had not extended beyond the local area. The usual dosage of radiation was 2,400 r in air through each of two portals. The drug was given by mouth originally and later by intramuscular injection, or by instillation into the internal carotid artery, the dosage being adjusted according to the weight and hematological response of the patient. The tumor was arrested and vision preserved, as judged from subsequent observation over a period of at least six months, in 12 out of 33 children who received the drug by mouth. Arrest of tumor growth and retention of useful vision was achieved in seven of eight children who received the drug intramuscularly. The intracarotid route was used in nine far advanced cases that had been classified as "almost hopeless"; in this group the tumor was arrested and useful vision preserved in two cases. The results have been better than those obtained in the past in comparable series with radiotherapy alone. Therapeutic doses of triethylene melamine produce hematological depression, and complete blood cell and platelet counts are a necessary and useful guide to the dosage and prevention of potentially severe toxic reaction in these cases. Given by mouth, the drug produced the maximum leukopenia in about nine days; given intramuscularly, it required about half that time. The latter route is definitely preferred.


Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours




Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.